2-溴-1-(3,4-二氢-1,5-苯并氧-7-)乙酮 | 35970-34-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(3,4-二氢-1,5-苯并氧-7-)乙酮
• 中文别名: 7-溴乙酰基-3,4-二氢-1,5-苯并二噁庚
• 英文名称: 2-bromo-1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-1-ethanone
• 英文别名: 2-bromo-1-(3,4-dihydro-2H-benzo[b]1,4-dioxepin-7-yl)ethanone；7-bromoacetyl-3,4-dihydro-1,5 benzodioxepin；2-bromo-1-(3,4-dihydro-2H-benzo[b][1,4]dioxepin -7-yl)ethan-1-one；Brommethyl-3,4-dihydro-1,5-benzodioxepin-7-yl-keton；3,4-(trimethylenedioxy)phenacyl bromide；2-Bromo-1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)ethan-1-one；2-bromo-1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)ethanone
• CAS: 35970-34-4
• 化学式: C₁₁H₁₁BrO₃
• mdl: MFCD00218462
• 分子量: 271.111
• InChiKey: YJSZSLGVTLSCRU-UHFFFAOYSA-N

物化性质

• 熔点：
  73-75°C
• 沸点：
  373.8±37.0 °C(Predicted)
• 密度：
  1.499±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常规情况下不会分解，也没有危险的反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  UN1759
• 储存条件：
  密封、阴凉、干燥、通风保存

SDS

Name:	2-Bromo-1-(3 4-dihydro-2H-1 5-benzodioxepin-7-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:	3,4-Trimethylenedioxyphenacylbromid
CAS:	35970-34-4

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(3 4-dihydro-2H-1 5-benzodioxepin-7-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:3,4-Trimethylenedioxyphenacylbromid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35970-34-4	2-Bromo-1-(3,4-dihydro-2H-1,5-benzodio	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35970-34-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 73 - 75 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11BrO3
Molecular Weight: 271

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35970-34-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 35970-34-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 35970-34-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35970-34-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-(3,4-二氢-1,5-苯并氧-7-)乙酮 以 乙酸乙酯 为溶剂， 生成 (S)-N-[1-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-(3-quinolylmethanesulfonyl)ethyl]-N-hydroxyformamide
  参考文献：
  名称：

  Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides

  摘要：

  式(I)的化合物：1R是氢，烷基，烯基，炔基，芳基，杂芳基或杂环烷基；和R1是双环烷基或杂双环烷基，对由s-CD23介导的疾病的治疗和预防具有用处。

  公开号：

  US20040024066A1
• 作为产物：
  描述：

  邻苯二酚 在 溴 、 potassium carbonate 、 zinc(II) chloride 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 2-溴-1-(3,4-二氢-1,5-苯并氧-7-)乙酮
  参考文献：
  名称：

  保护儿茶酚二羟基的有效策略

  摘要：

  已开发出一种保护儿茶酚二羟基的新策略。邻苯二酚与 1,3-二溴丙烷的碱介导环化提供了相应的苯并[b]1,4-二氧杂环己烷，因此保护基团很容易被氯化铝裂解。由邻苯二酚制备抗菌和抗真菌剂 4-(2-aminothiazol-4-yl)benzo-1,2-diol 可靠地验证了其适用于各种苛刻反应条件的可用性。

  DOI：

  10.1055/s-0032-1318332

文献信息

• Iron-Catalyzed Synthesis of 2-Aminofurans from 2-Haloketones and Tertiary Amines or Enamines
  作者：Le-Cheng Wang、Hui-Qing Geng、Jin-Bao Peng、Xiao-Feng Wu

  DOI：10.1002/ejoc.202000293

  日期：2020.5.10

  An interesting iron‐catalyzed protocol for the synthesis of 2‐aminofurans has been developed. Starting from 2‐haloketones and tertiary amines or enamines, various 2‐aminofurans were produced in good yields.

  已经开发了一种有趣的铁催化合成2-氨基呋喃的方法。从2-卤代酮和叔胺或烯胺开始，各种2-氨基呋喃的收率很高。
• 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer
  作者：Sahar Kandil、Andrew D. Westwell、Christopher McGuigan

  DOI：10.1016/j.bmcl.2016.02.088

  日期：2016.4

  The clinically used androgen receptor (AR) antagonists (bicalutamide, flutamide and nilutamide) bind with low affinity to AR and can induce escape mechanisms. Furthermore, under AR gene amplification or mutation conditions they demonstrate agonist activity and fail to inhibit AR, causing relapse into castration resistant prostate cancer (CRPC). Discovery of new scaffolds distinct from the 4-cyano/

  临床上使用的雄激素受体（AR）拮抗剂（比卡鲁胺，氟他胺和尼鲁米特）对AR的亲和力低，并且可以诱导逃逸机制。此外，在AR基因扩增或突变条件下，它们表现出激动剂活性并且不能抑制AR，导致复发为去势抵抗性前列腺癌（CRPC）。迫切需要发现不同于当前使用的抗雄激素共有的4-氰基/硝基-3-（三氟甲基）苯基的新型支架，以避免与这些化合物产生交叉耐药性。在这项研究中，制备了一系列的29个7-取代的伞形酮衍生物，并评估了它们的抗增殖活性。活性最高的化合物7a在人前列腺癌细胞系（22Rv1）中表现出亚微摩尔抑制活性；我知道了50  = 0.93μM，比临床抗雄激素比卡鲁胺（IC 50  = 46μM）提高了50倍，比恩杂鲁胺（IC 50 = 32μM）提高了30倍以上 。有趣的是，该化合物对人乳腺癌细胞系（MCF-7）的活性更高。IC 50  = 0.47μM。分子建模研究为我们的发现提供了合理的理论解释。
• Synthesis and structure–activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis
  作者：Emanuela Pesce、Marta Bellotti、Nara Liessi、Sara Guariento、Gianluca Damonte、Elena Cichero、Andrea Galatini、Annalisa Salis、Ambra Gianotti、Nicoletta Pedemonte、Olga Zegarra-Moran、Paola Fossa、Luis J.V. Galietta、Enrico Millo

  DOI：10.1016/j.ejmech.2015.05.030

  日期：2015.6

  targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide

  囊性纤维化跨膜电导调节剂 (CFTR) 是存在于上皮细胞膜中的氯离子通道。影响CFTR的突变基因导致囊性纤维化（CF），一种多器官严重疾病。最常见的 CF 突变 F508del 会损害 CFTR 蛋白的加工和活性（门控）。其他突变，如 G551D，只会导致门控缺陷。加工和门控缺陷可以分别被称为一般校正剂和增强剂的小分子作为目标。氨基芳基噻唑 (AAT) 代表了一类有趣的化合物，包括具有双重活性的分子，作为校正剂和增强剂。为了改善 AAT 的活性特征，我们现在设计并合成了一个新化合物库，以建立一个初始 SAR，该 SAR 可以提供有关对救援活动有益或有害的化学基团的指示。使用功能测定法在表达 CFBE41o 的 F508del-CFTR 中测试了新化合物作为校正剂和增强剂。双重活性化合物 AAT-如图 4a 所示，当与校正剂 VX-809 组合时，其特征在于提高的功效和显着的协同作用。此外，通过计算方法，已检测到核苷酸结合域
• Diaminothiazoles having antiproliferative activity
  申请人：——

  公开号：US20020151554A1

  公开（公告）日：2002-10-17

  Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

  揭示了一种新型的二氨基噻唑，它们是Cdk4的选择性抑制剂。这些化合物及其药学上可接受的盐和酯是抗增殖剂，在治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺肿瘤方面非常有用。还公开了含有这些化合物的药物组合物，以及制备这些化合物的中间体。
• [EN] 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL- OU 2-HÉTARYL-IMIDAZOL[1,2-A]PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014177458A1

  公开（公告）日：2014-11-06

  The invention relates to compounds of formulas I and II, formula I or formula II wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, S-lower alkyl, lower alkoxy substituted by halogen, di-lower alkyl amino, C(O)O-lower alkyl, lower alkyl substituted by hydroxy or hydroxy; R2 is hydrogen, lower alkyl, halogen, lower alkoxy, S-lower alkyl, lower alkoxy substituted by halogen, O(CH2)2-lower alkoxy substituted by halogen, di-lower alkyl amino, alkyl amino, NH-lower alkyl substituted by halogen, N(lower alkyl)-benzyl, lower alkyl substituted by hydroxy, heterocycloalkyl optionally substituted by halogen, CH2-lower alkoxy, CH2-lower alkoxy substituted by halogen or hydroxy; or R1 and R2 form together with the carbon atoms to which they are attached a ring containing -OCH2CH2O-, OCH2O-, OCH2CH2CH2O- or -NHC(O)CH2O-; R3 is hydrogen or lower alkoxy; R4 is hydrogen or lower alkyl; R5 is lower alkyl, cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or R4 and R5 form together with the nitrogen atom to which they are attached a ring containing -CH2CH2CHRCH2CH2-, -CH2CHRCH2CH2-, -CH2CH2OCH2CH2-, -CH2CH2NR'CH2CH2-, CH2CHR- or -CH2CH2CH2-; wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R' is lower alkyl substituted by halogen; Ra is hydrogen or H; Rb is hydrogen, hydroxy or 3H; R6 is hydrogen, halogen or lower alkyl; HetAr is selected from the group consisting of thiophenyl, furanyl, thiozolyl, benzofuranyl, pyrazolyl, benzoimidazolyl or pyridinyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The present compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.

  本发明涉及式I和式II的化合物，式I或式II中，R1为氢、低级烷基、低级烷氧基、卤素、S-低级烷基、卤素取代的低级烷氧基、二-低级烷基氨基、C(O)O-低级烷基、羟基取代的低级烷基或羟基；R2为氢、低级烷基、卤素、低级烷氧基、S-低级烷基、卤素取代的低级烷氧基、O(CH2)2-卤素取代的低级烷氧基、二-低级烷基氨基、烷基氨基、NH-卤素取代的低级烷基、N(低级烷基)-苄基、羟基取代的低级烷基、任选卤素取代的杂环烷基、CH2-低级烷氧基、CH2-卤素或羟基取代的低级烷氧基；或者R1和R2与其所连接的碳原子一起形成含有-OCH2CH2O-、OCH2O-、OCH2CH2CH2O-或-NHC(O)CH2O-的环；R3为氢或低级烷氧基；R4为氢或低级烷基；R5为低级烷基、环烷基、羟基取代的低级烷基或卤素取代的低级烷基；或者R4和R5与其所连接的氮原子一起形成含有-CH2CH2CHRCH2CH2-、-CH2CHRCH2CH2-、-CH2CH2OCH2CH2-、-CH2CH2NR'CH2CH2-、CH2CHR-或-CH2CH2CH2-的环；其中R为氢、卤素、低级烷基、低级烷氧基或卤素取代的低级烷基；R'为卤素取代的低级烷基；Ra为氢或H；Rb为氢、羟基或3H；R6为氢、卤素或低级烷基；HetAr选自噻吩基、呋喃基、噻唑基、苯并呋喃基、吡唑基、苯并咪唑基或吡啶基；n为1或2；或为药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。本发明的化合物适合作为成像工具，通过识别大脑中tau聚集体过量的潜在患者，将有助于改善诊断，这些患者可能发展为阿尔茨海默病。